REG - Fiske PLC - Exercise of Share Options and Issue of Equity

FiskeAnnouncement

17/09/2021 10:00

RNS Number : 1461M
  
Fiske PLC
  
17 September 2021
  
 

17 September 2021
 
 
Fiske Plc
('Fiske' or 'the Company')
Exercise of Share Options and Issue of Equity
Fiske announces that, following the exercise of share options by a former employee, the Company has today issued 75,000 ordinary shares of 25p each ('Ordinary Shares') at the exercise price of 28.75p per Ordinary Share. 
Application has been made for the 75,000 Ordinary Share, which will rank pari passu with the Company's existing issued Ordinary Shares, to be admitted to trading on AIM. It is expected that admission will become effective and that trading in the shares will commence on or around 22 September 2021 ("Admission").
Following Admission, the Company will have 11,829,859 Ordinary Shares in issue. The Company holds no shares in treasury. Accordingly, the figure of 11,829,859 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information please contact:
 
  • Samantha Harrison/Harrison Clarke, Grant Thornton UK LLP (Nominated Adviser)
    (tel: 020 7383 5100)
 
  • James Harrison, Fiske Plc - CEO
    (tel: 020 7448 4700)
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
IOEFIFETARIDLIL